These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 30392810

  • 1. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T, Kulasingam S, Mayrand MH, Ogilvie G, Smith L, Bouchard C, Gotlieb W, Franco EL.
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [Abstract] [Full Text] [Related]

  • 2. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X, Zhang H, Zhang H, Xiao Y, Zhong F, Zhou X, Cong Q, Sui L, Zhao C.
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [Abstract] [Full Text] [Related]

  • 3. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, Hammond I, Canfell K.
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.
    J Natl Cancer Inst; 2005 Jul 20; 97(14):1072-9. PubMed ID: 16030305
    [Abstract] [Full Text] [Related]

  • 6. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics.
    Zejnullahu Raçi P, Hošnjak L, Poljak M, Lepej SŽ, Vince A.
    Ginekol Pol; 2018 Jul 20; 89(9):485-494. PubMed ID: 30318575
    [Abstract] [Full Text] [Related]

  • 7. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.
    Int J Cancer; 2017 Dec 15; 141(12):2410-2422. PubMed ID: 28801947
    [Abstract] [Full Text] [Related]

  • 8.
    Kulasingam SL, Havrilesky L, Ghebre R, Myers ER.
    ; 2011 05 15. PubMed ID: 22553886
    [Abstract] [Full Text] [Related]

  • 9. Are 20 human papillomavirus types causing cervical cancer?
    Arbyn M, Tommasino M, Depuydt C, Dillner J.
    J Pathol; 2014 Dec 15; 234(4):431-5. PubMed ID: 25124771
    [Abstract] [Full Text] [Related]

  • 10. Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework.
    Xu L, Padalko E, Oštrbenk A, Poljak M, Arbyn M.
    Int J Mol Sci; 2018 Sep 11; 19(9):. PubMed ID: 30208597
    [Abstract] [Full Text] [Related]

  • 11. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA, U.S. Preventive Services Task Force.
    Ann Intern Med; 2012 Jun 19; 156(12):880-91, W312. PubMed ID: 22711081
    [Abstract] [Full Text] [Related]

  • 12. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.
    GMS Health Technol Assess; 2010 Apr 27; 6():Doc05. PubMed ID: 21289878
    [Abstract] [Full Text] [Related]

  • 13. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R.
    Lancet; 2020 Feb 22; 395(10224):575-590. PubMed ID: 32007141
    [Abstract] [Full Text] [Related]

  • 14. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G, Esteban E, Widschwendter A, Oberaigner W, Borena W, von Laer D, Hackl M, Endel G, Siebert U.
    Int J Cancer; 2020 Aug 15; 147(4):1131-1142. PubMed ID: 31872420
    [Abstract] [Full Text] [Related]

  • 15. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT, Smith MA, Lew JB, O'Hallahan J, Fentiman G, Neal H, Sage M, Canfell K.
    Gynecol Oncol; 2019 Mar 15; 152(3):472-479. PubMed ID: 30876491
    [Abstract] [Full Text] [Related]

  • 16. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.
    Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D'Souza G, Watts DH, Levine AM, Castle PE, Colie C, Palefsky JM, Strickler HD.
    JAMA; 2012 Jul 25; 308(4):362-9. PubMed ID: 22820789
    [Abstract] [Full Text] [Related]

  • 17. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
    Ali MAM, Bedair RN, Abd El Atti RM.
    Cancer Cytopathol; 2019 Sep 25; 127(9):567-577. PubMed ID: 31390155
    [Abstract] [Full Text] [Related]

  • 18. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
    Castanon A, Landy R, Pesola F, Windridge P, Sasieni P.
    Lancet Public Health; 2018 Jan 25; 3(1):e34-e43. PubMed ID: 29307386
    [Abstract] [Full Text] [Related]

  • 19. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.
    Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, Hamada H, Yoshikawa H.
    Cancer Sci; 2009 Jul 25; 100(7):1312-6. PubMed ID: 19432906
    [Abstract] [Full Text] [Related]

  • 20. Age-specific 3-year cumulative risk of cervical cancer and high-grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting.
    Ge Y, Christensen PA, Luna E, Armylagos D, Xu J, Hsu JW, Zhou H, Schwartz MR, Mody DR.
    Cancer Cytopathol; 2019 Dec 25; 127(12):757-764. PubMed ID: 31589379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.